Market expansion ProNova is pursuing broader global access to proton therapy with a compact, cost-efficient system. This presents opportunities to partner with hospitals and clinics in emerging markets seeking advanced cancer treatment capabilities at lower total cost of ownership.

Financing leverage With seed funding of 13.5M and a total funding pool of around 40M, ProNova may be open to strategic investments, joint ventures, or customer financing partnerships to accelerate adoption and deployment of their compact proton systems.

Strategic leadership Recent leadership appointment of Dr. Moataz Karmalawy as CEO and SVP indicates a focus on execution and partnerships. This creates a favorable entry point for enterprise sales discussions and executive sponsorship opportunities.

Clinical and operational value The integrated offering combining advanced imaging, multi-axis positioning, superconducting magnets, and closed-loop PET verification highlights a clear ROI in patient outcomes and treatment efficiency, useful for value-based selling andROI-focused proposals to hospital procurement.

Industry collaboration Ongoing collaborations for ultra-compact, high-performance systems and participation in industry events (SEE Symposium, NPC 2026) signals readiness for co-marketing, pilot deployments, and case studies with key cancer centers and research institutions.